Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 1
2018 6
2019 3
2020 1
2021 7
2022 7
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus.
Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, Izumi N. Tamaki N, et al. Among authors: kojima y. Hepatol Commun. 2022 Mar;6(3):461-472. doi: 10.1002/hep4.1833. Epub 2021 Oct 22. Hepatol Commun. 2022. PMID: 34676692 Free PMC article.
Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.
Kaneko S, Kurosaki M, Joko K, Marusawa H, Kondo M, Kojima Y, Uchida Y, Kimura H, Tsuji K, Yagisawa H, Kusakabe A, Kobashi H, Akahane T, Tamaki N, Kirino S, Abe T, Yoshida H, Matsushita T, Hasebe C, Izumi N. Kaneko S, et al. Among authors: kojima y. Sci Rep. 2020 Aug 3;10(1):13021. doi: 10.1038/s41598-020-69522-w. Sci Rep. 2020. PMID: 32747646 Free PMC article.
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
Mashiba T, Joko K, Kurosaki M, Ochi H, Marusawa H, Uchida Y, Fujii H, Kojima Y, Yoshida H, Goto T, Akahane T, Kondo M, Tsuji K, Mitsuda A, Hasebe C, Kusakabe A, Sohda T, Furuta K, Kobashi H, Ogawa C, Ide Y, Arai H, Okada K, Shigeno M, Nonogi R, Izumi N. Mashiba T, et al. Among authors: kojima y. J Viral Hepat. 2022 Jul;29(7):551-558. doi: 10.1111/jvh.13684. Epub 2022 May 18. J Viral Hepat. 2022. PMID: 35548866
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S, Kurosaki M, Mashiba T, Marusawa H, Kondo M, Kojima Y, Uchida Y, Fujii H, Akahane T, Yagisawa H, Kusakabe A, Kobashi H, Abe T, Yoshida H, Ogawa C, Furuta K, Tamaki N, Tsuji K, Matsushita T, Izumi N; Japanese Red Cross Liver Study Group. Kaneko S, et al. Among authors: kojima y. J Med Virol. 2023 Jan;95(1):e28210. doi: 10.1002/jmv.28210. Epub 2022 Oct 20. J Med Virol. 2023. PMID: 36222204
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.
Yasui Y, Kurosaki M, Tsuchiya K, Hayakawa Y, Hasebe C, Abe M, Ogawa C, Joko K, Ochi H, Tada T, Nakamura S, Furuta K, Kimura H, Tsuji K, Kojima Y, Akahane T, Tamada T, Uchida Y, Kondo M, Mitsuda A, Izumi N; Japanese Red Cross Liver Study Group. Yasui Y, et al. Among authors: kojima y. Cancers (Basel). 2022 Jun 16;14(12):2975. doi: 10.3390/cancers14122975. Cancers (Basel). 2022. PMID: 35740647 Free PMC article.
Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.
Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Tateishi R, et al. J Gastroenterol. 2021 Mar;56(3):261-273. doi: 10.1007/s00535-020-01754-z. Epub 2021 Jan 11. J Gastroenterol. 2021. PMID: 33427937 Free PMC article.
A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response.
Tada T, Kurosaki M, Tamaki N, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N. Tada T, et al. Among authors: kojima y. JGH Open. 2021 Dec 8;6(1):20-28. doi: 10.1002/jgh3.12690. eCollection 2022 Jan. JGH Open. 2021. PMID: 35071784 Free PMC article.
General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy.
Tada T, Kurosaki M, Tamaki N, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Fujii H, Ishii T, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N. Tada T, et al. Among authors: kojima y. JGH Open. 2022 Jun 8;6(7):487-495. doi: 10.1002/jgh3.12778. eCollection 2022 Jul. JGH Open. 2022. PMID: 35822118 Free PMC article.
25 results